Genomic Vision to Present at the LD Micro Main Event

Regulatory News:

Genomic Vision (Paris:GV) (GV: EN Paris), a French molecular diagnostics company specializing in the development of diagnostic tests for genetic diseases and cancers based on molecular combing technology, today announced that it will be presenting at the 8^th annual LD Micro Main Event at the Luxe Sunset Bel Air Hotel (Los Angeles) on Thursday, December 3^rd at 3:00 p.m. PST/6:00 p.m. EST. Aaron Bensimon, Ph.D., CEO & President of Genomic Vision, will be giving the presentation and meeting with investors.

A live audio webcast of Dr. Bensimon’s presentation will be available in the investor section of Genomic Vision’s website, www.genomicvision.com, where it will also be archived for 90 days.

The conference features over 200 companies in the small/micro-cap space.

ABOUT GENOMIC VISION

Founded in 2004, Genomic Vision is a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing. Using this innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. The Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France. Genomic Vision has been listed on Compartment C of Euronext Paris since April 2014.

For further information, please go to www.genomicvision.com

Member of CAC^® Mid & Small, CAC^® All-Tradable and EnterNext© PEA-PME 150 indexes

View source version on businesswire.com: http://www.businesswire.com/news/home/20151201006405/en/